PERTH, Australia - Pfizer's Phase IIIb Asian trial of its leading oncology drug multi-kinase inhibitor Sutent demonstrated similar effectiveness and tolerability in Asians as in non-Asians, in data the company released Sept. 21. Conducted at 246 sites in 52 countries, including Korea, Hong Kong, Malaysia, Philippines, Singapore, Taiwan and Thailand, the prospective Phase IIIb study evaluated safety and efficacy of sunitinib in Asian patients with metastatic renal cell carcinoma. It was conducted...